KDM5B inhibits initiation of leukaemogenesis in leukaemias expressing MLL fusion proteins by reducing the high levels of H3K4me3 required by the leukaemic stem cells (LSCs) for proliferation. This evidence concerns the gene KDM5B and leukemia.